Dyslipidemia

The daily therapy was tested for T2D control benefits and treatment adherence versus insulin glargine U-300.

IgE for alpha-gal was identified in 26% of the patients, and plaque buildup was 30% higher in those patients compared to those that were not sensitized.

Today, the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 12-8 in favor of approval of volanesorsen (Waylivra) for the treatment of familial chylomicronemia syndrome (FCS).

From fruit juice to fibrates to fluvastatin, what do you know about the safety of specific statin interactions?

Akcea Therapeutics announced that it has expanded its global early access program to the US for its drug volanesorsen, which is in development for treatment of the rare lipid disorder FCS.

As stated in article published in the clinical journal Neurobiology of Aging, a team of researchers has discovered that elevated levels of certain types of lipids in the brain could be an early presentation of Parkinson’s disease.

Treatment with volanesorsen shows efficacy in patients with FCS.

Results from a questionnaire show that individuals living with FCS prove that communication among people in similar situations can improve a patient’s quality of life.

At the NLA Scientific Sessions, Akcea Therapeutics presented a poster with data from 2 different studies, each of which exhibited a significant reduction of triglycerides in patients with FCS when administered volanesorsen.

At the NLA Scientific Sessions in Las Vegas this morning, Akcea Therapeutics, presented a poster with data from the largest burden of illness study in patients with FCS to date.

At the NLA Scientific Sessions in Las Vegas, NV this weekend, Akcea Therapeutics will present clinical data on volanesorsen and FCS.

Patients who consumed vinegar daily along with a restricted calorie diet lost more weight and saw improved BMI scores compared to those just on the diet.

Black patients had a 62% greater chance of having experienced an ischemic stroke pre-AF diagnosis, and a 67% higher risk of having one post-AF diagnosis.

Akcea announced that the Division of Metabolism and Endocrinology Products of the U.S. FDA will hold an advisory committee meeting to review data supporting the NDA for volanesorsen.